Levetiracetam Tablet, Film Coated
Product Images NDC 68001-404

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 68001-404). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Levetiracetam Tablets Usp 250mg (Image 01)

This text is a medication label for Levetiracetam USP 250 mg tablets by Aurobindo Pharma Limited. It includes dosage recommendations for the drug and instructions for pharmacists to dispense it in a light-resistant container. The medication should be stored between 20°C to 25°C (68°F to 77°F) or between 15°C to 30°C (59°F to 86°F). The text also includes product codes and manufacturing information.*

FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)

The figure shows the responder rate in Study 1 which resulted in a 250% reduction from baseline. The percentages range from 0% to 39.6%, with the statistically significant result indicated as compared to placebo. The text also mentions the use of Leviaseam at different concentrations.*

FDA Label Image

Levetiracetam Tablets Usp 1000mg (Levetiracetam Fig10)

This is a medication bottle label for Levetiracetam Tablets USP with a strength of 1000 mg. The label provides information for the pharmacist to dispense the medication with the provided medication guide. The recommended dosage can be found in the package insert. The medication should be dispensed in a light-resistant container and stored at temperatures between 20°C to 25°C. The medication is manufactured by Aurobindo Pharma Limited in Hyderabad, India, and is distributed by BluePoint Laboratories. The label also includes a product code, batch number, and revision date.*

FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)

The image shows the responder rates of patients in Study 2 for a specific period, with a comparison between the placebo group and two groups taking different doses of the medication Levetiracetam. One of the Levetiracetam dosages resulted in a statistically significant improvement compared to the placebo group.*

FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)

The text describes a figure, which shows the responder rate of two groups in "Study 3". The figure shows a chart with percentages on the y-axis and two groups, "Placebo" and "Levetiracetam 3000 mg/day", on the x-axis. The responder rate, defined as a >50% reduction from baseline, for each group is shown as a bar in the chart. The Levetiracetam group has a higher responder rate (45%) than the Placebo group (39.4%). The figure also notes that the difference between the two groups is statistically significant.*

FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)

The text describes a figure (Figure 4), which shows the responder rate in a study (Study 4) based on a 50% reduction from baseline. The figure demonstrates that the responder rates for the placebo group and the group treated with Levetiracetam were 44.6% and 45%, respectively. The graph also indicates that the Levetiracetam group demonstrated a statistically significant difference compared to the placebo group.*

FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

The text is describing a figure labeled "Figure 5" which shows the Responder Rate for patients between the ages of 1 month to less than 4 years. The rate is plotted as a percentage, with Lovetracatam and Placebo being the two treatments being compared. Lovetracatam had a statistically significant (>50%) reduction from baseline compared to Placebo.*

FDA Label Image

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

FDA Label Image

Levetiracetam Tablets Usp 500mg (Levetiracetam Fig8)

This is a medication called Levetiracetam in the form of tablets. Each film-coated tablet contains 500mg of Levetiracetam USP. It is manufactured by Aurobindo Pharma Limited in Hyderabad, India, and sold by BluePoint Laboratories in a bottle of 120 tablets. The recommended dosage is available in the package insert. Pharmacists are advised to dispense it in a tightly closed, light-resistant container with a child-resistant closure. It has to be stored at room temperature between 20°C to 25°C and excursions permitted to 15°C to 30°C. However, the text doesn't provide any information regarding the unwinding direction.*

FDA Label Image

Levetiracetam Tablets Usp 750mg (Levetiracetam Fig9)

This is a description of a medication called Levetiracetam. It is in the form of film-coated tablets with a dosage of 750 mg. The recommended dosage should be obtained from the package insert. The pharmacist should dispense it in a tightly packed light-resistant container with a child-resistant closure. The medication guide should be provided separately to the patient. It should be stored at a temperature range of 20°C to 25°C and excursions are permitted from 15°C to 30°C. The manufacturer is Aurobindo Pharma Limited located in Hyderabad, India. *

FDA Label Image

Chemical Structure (Levetiracetam Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.